Loading...
Loading...
MRTX| Name | Value |
|---|---|
| Revenues | 7.2M |
| Cost of Revenue | 0.8M |
| Gross Profit | 6.3M |
| Operating Expense | 200.2M |
| Operating I/L | -193.8M |
| Other Income/Expense | 9.2M |
| Interest Income | 0.0M |
| Pretax | -184.6M |
| Income Tax Expense | -9.2M |
| Net Income/Loss | -175.3M |
Mirati Therapeutics, Inc. is a clinical-stage oncology company focused on developing product candidates targeting genetic and immunological drivers of cancer. Its lead product, MRTX849, a KRAS G12C inhibitor, is in Phase 1/2 clinical trial for non-small cell lung, colorectal, pancreatic, and other cancers. Additionally, the company is developing Sitravatinib, a spectrum-selective kinase inhibitor in Phase 3 clinical trial for NSCL cancer, and a KRAS G12D inhibitor program in preclinical development. Mirati has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib.
